Symbiotec Pharmalab

About Symbiotec Pharmalab

Symbiotec Pharmalab, founded by Anil Satwani in 2002, is a pharmaceutical and biotechnology company specializing in Active Pharmaceutical Ingredients (APIs), with a focus on corticosteroids and steroidal hormones. Anil Satwani, the Chairman and Managing Director, has over three decades of experience in the pharmaceutical industry and has guided the company's evolution from a small-scale steroid manufacturer to a diversified global entity. The company is headquartered in Indore, India, and has grown to serve over 200 customers across more than 40 countries. The company's business model is centered on a vertically integrated 'farm/microbe-to-pharmacy' framework, which involves significant in-house capabilities in organic chemistry, biotechnology, and complex injectables. This backward integration allows Symbiotec to manufacture over 80% of its key starting materials, reducing reliance on external suppliers and controlling costs and quality. Revenue is primarily generated from the sale of its own APIs, which accounted for approximately 96% of operating revenue in Fiscal Year 2026. The company also provides Contract Development and Manufacturing Organization (CDMO) services to specialty pharmaceutical and nutraceutical companies, alongside developing complex injectable products. Symbiotec holds a significant position in the global market, with a reported 36.2% volume share in corticosteroid APIs and a 44.2% share in steroidal-hormone APIs as of FY2025. Its product portfolio includes over 60 APIs, with key products being Hydrocortisone, Testosterone, and Methylprednisolone. The company operates multiple manufacturing facilities in Madhya Pradesh, India, including sites in Rau, Pithampur, Ujjain, and Mhow, which are compliant with regulations from bodies like the US FDA. A notable milestone includes receiving a strategic investment from the late Rakesh Jhunjhunwala in 2007. The company has since attracted further private equity investment and launched an IPO in August 2026 to facilitate partial exits for investors and fund further growth.